ReviewInternational journal of hematology2015
Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.
Review in International journal of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient.Blood advances · 2019Trial
- Chronic graft-versus-host disease myelitis successfully treated with rituximab.International journal of hematology · 2025Article
- Successful Haematopoietic Stem Cell Transplantation for LRBA Deficiency with Fludarabine, Treosulfan, and Thiotepa-Based Conditioning.Journal of clinical immunology · 2024Article
- W"H-Y" antigen/HLA complexes in chronic GVHD.Blood · 2023Article
- CD56bright CD16- natural killer cells as an important regulatory mechanism in chronic graft-Haematologica · 2023Article
- Mangiferin Promotes Bregs Level, Activates Nrf2 Antioxidant Signaling, and Inhibits Proinflammatory Cytokine Expression in Murine Splenic Mononuclear Cells In Vitro.Current medical science · 2021Article
- Anaerobic Antibiotics and the Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Article
- New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.Frontiers in immunology · 2020Review
- Different Immune Reconstitution between Cord Blood and Unrelated Bone Marrow Transplantation with Relation to Chronic Graft-versus-Host Disease.International journal of hematology-oncology and stem cell research · 2020Article
- Increased CD83 expression of CD34-positive monocytes in donors during peripheral blood stem cell mobilization in humans.Scientific reports · 2019Article
- Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant.Blood advances · 2018Article
- OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics.Journal of immunology research · 2018Article
- Protective Effect of Rituximab in Chronic Graft-Versus-Host Disease Occurrence in Allogeneic Transplant patients with Epstein Barr Virus Viremia.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Article
- Article
- The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease.Biomedicines · 2017Review
- Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes.Haematologica · 2016Article
- Comparative In Vitro Immune Stimulation Analysis of Primary Human B Cells and B Cell Lines.Journal of immunology research · 2016Article
- Recent topics in graft-versus-host disease: from the perspectives of pathogenesis and treatment.International journal of hematology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) can be a curative strategy for hematological diseases, and the indications for allo-HCT have broadened widely due to recent progress in supportive strategies. However, patients must overcome various complications and chronic graft-versus-host disease (cGVHD) remains the most common allo-HCT cause of long-term morbidity and mortality. cGVHD is difficult to biologically assess due to the heterogeneity of cGVHD symptoms, and the pathogenesis of cGVHD has yet to be established. Recent experimental model progress has suggested that B-cells play a critical role in cGVHD development. Consistent with these experimental results, some clinical studies investigating B-cell depletion and modulation of B-cell signaling pathways have decreased cGVHD incidence and provided some therapeutic benefit. However, randomized control studies are necessary to confirm the efficacy of B-cell targeting drugs for cGVHD. Here, we review the pathophysiology of cGVHD, especially focusing on the role of B-cell immunity, and discuss the efficacy of both B-cell depletion and modulation of B-cell signaling pathways in human cGVHD prevention, initial treatment, and salvage treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.